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Background: Reports presented at European Society of Cardiology (ESC) 2006 meeting about increased mortality associated with drug-eluting 
stents (DES), possibly due to late stent thrombosis, sparked controversy and prompted the U.S. Food and Drug Administration to recommend using 
DES according to label indications only. In early 2007, pooled analyses with longer follow up disproved the controversial findings. We studied how 
these developments affected stent use at our institution.
Methods: Data from internal database between April 2003 and January 2009 were analyzed. Three periods of interest were specified: 1) prior 
to ESC 2006 meeting (4/2003 - 9/2006), 2) soon after ESC 2006 meeting (9/2006 - 8/2007) and 3) late after ESC 2006 meeting (9/2007 - 
1/2009). All percutaneous coronary intervention (PCI) cases with stent placement were analyzed.
Results: A total of 11,926 PCI were performed by 15 operators. Mean age of patients was 65 years; 65% were males. Overall DES use declined 
across the 3 periods from 83% to 70% to 63% of all stents, p < 0.0001 (Table). DES use in acute myocardial infarction (AMI) decreased from 84% 
to 61% to 48%, a steeper decline compared to overall DES use, p < 0.0001. Bare metal stent (BMS) use increased proportionally throughout.
Conclusions: In this community hospital experience, there has been continued decrease in use of DES, despite resolution of DES controversy. A 
steeper decline in DES use was observed in AMI, currently an off label indication.
Table: Trends in DES use 
All PCI
(on-label and off-label)
Prior to ESC 2006 
meeting (4/2003 - 
9/2006)
Soon after ESC 2006 
meeting (9/2006 - 9/2007)
Late after ESC 2006 meeting 
(9/2007 - 1/2009)
All Stents 10,724 2,472 3,441
DES 8,875 (83%) 1,740 (70%) 2,180 (63%)
BMS 1,849 (17%) 732 (30%) 1,261 (37%)
AMI
(off-label)
AMI stents 3,933 509 763
DES 3,304 (84%)† 309 (61%) 367 (48%)
BMS 801 (20%) 212 (41%) 411 (54%)
p <0.0001 for all trends; †- Some patients with AMI received both DES and BMS
